Qiagen NV (NYSE: QGEN) shares have been on the rise after new reports said the company is exploring “strategic options,” including a possible sale. Recent…
July 09, 2026
July 09, 2026
Delcath Systems Starts Phase 2 HEPZATO Trial in Liver-Dominant Metastatic Breast Cancer
Delcath Systems Inc. (NASDAQ: DCTH) has dosed the first patient in its Phase 2 clinical trial evaluating HEPZATO in people with liver-dominant metastatic breast cancer…
World Vitiligo Day 2026 carries the theme “Look How Far We’ve Come: A Journey of Resilience, Strength, and Beauty,” marking a decade of progress for…
June 11, 2026
Novartis and Orionis Double Down: 1.4B Molecular Glue Pact Targets “Undruggable” Diseases
Novartis (NYSE: NVS) has expanded its collaboration with Orionis Biosciences in a multi‑year molecular glue drug discovery deal that includes 40 million dollars upfront and…
Parabilis Medicines’ (NASDAQ: PBLS) Wall Street debut just reset the bar for biotech IPOs, with the cancer‑focused peptide company raising 670 million dollars in an…
Conexeu Sciences (NASDAQ: CNXU) stock is getting a lift as the company checks off key steps toward bringing its lead wound care device, CXU, into the…
Roche Holding AG (OTC: RHHBY) is making a major push deeper into targeted protein degradation, signing a deal worth up to 2.3 billion dollars with…
Tango Therapeutics Inc. (NASDAQ: TNGX) just delivered the kind of data that can reset a small‑cap oncology name, with shares soaring over 30% after new…
Biogen Inc., (NASDAQ: BIIB) is quietly strengthening its rare‑disease pipeline, with its investigational spinal muscular atrophy (SMA) therapy salanersen earning a coveted Breakthrough Therapy designation…
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has released new interim clinical data showing that its experimental obesity and liver disease drug ARO‑INHBE meaningfully cuts liver fat…
PharmaTher Holdings Ltd. (OTCQB: PHRRF) is reshaping its business around MEDBOTX™, a robotic 3D‑printing platform designed to produce personalized medicines directly at the point of care….
Bayer (BAYN.DE) is acquiring privately held Perfuse Therapeutics in a transaction worth up to 2.45 billion dollars to expand and modernize its ophthalmology pipeline. The…